Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Open-label, Multicenter Phase Ib/Ⅱ Study to Evaluate the Safety, Tolerability, and Antitumor Activity of GB268 for Injection as Monotherapy or in Combination Regimens in Patients With Locally Advanced Unresectable or Metastatic Breast Cancer

NCT07738341 is registered in ClinicalTrials.gov with Eddingpharm (Zhuhai) Co., Ltd. as lead sponsor.

NCT NCT07738341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07738341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Open-label, Multicenter Phase Ib/Ⅱ Study to Evaluate the Safety, Tolerability, and Antitumor Activity of GB268 for Injection as Monotherapy or in Combination Regimens in Patients With Locally Advanced Unresectable or Metastatic Breast Cancer
Lead sponsor
Eddingpharm (Zhuhai) Co., Ltd.
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
August 1, 2026
Completion date
August 1, 2030
Enrollment
270 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (locally advanced or metastatic)